Zusammenfassung
Größte Gruppe der Antiallergika sind die wenig sedierenden H1-Antihistaminika, die vor allem zur Behandlung des Heuschnupfens, der allergischen Bindehautentzündung und der Urtikaria eingesetzt werden.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Abramson M, Puy R, Weiner J (2003): Allergen immunotherapy for asthma (Cochrane Review). In: The Cochrane Library, Issue 1, 2003. Oxford: Update Software.
Adelsberg BR (1997): Sedation and performance issues in the treatment of allergic conditions. Arch Intern Med 157:494–500.
Adkinson NF, Eggleston PA, Eney D, Goldstein EO, Schuberth KC et al. (1997): A controlled trial of immunotherapy for asthma in allergic children. N Engl J Med 336:324–331.
Arvidsson MB, Löwhagen O, Rak S (2002): Effect of 2-year placebo-controlled immunotherapy on airway symptoms and medication in patients with birch pollen allergy. J Allergy Clin Immunol 109: 777–783.
Austen KF (2001): Allergies, anaphylaxis, and systemic mastocytosis. In: Braunwald E et al. (eds): Harrison’s principles of internal medicine. McGraw-Hill Medical Publishing Division, New York, pp. 1913–1922.
Bousquet J, Hejjaoui A, Clauzel AM, Guerin B, Dhivert H, Skassa-Brociek W, Wichel FB (1988): Specific immunotherapy with a standardized Dermatophagoides pteronyssinus extract. II. Prediction of efficacy of immunotherapy. J Allergy Clin Immunol 82: 971–977.
Bousquet J, Scheinmann P, Guinnepain MT, Petrin-Fayolle M, Sauvaget J, Tonnel AB et al. (1999): Sublingual-swallow immunotherapy (SLIT) in patients with asthma due to house-dust mites: a double-blind, placebo-controlled study. Allergy 54: 249–260.
Canonica GW, Passalacqua G (2003): Noninjection routes for immunotherapy. J Allerg Clin Immunol 111: 437–448.
Day JH, Briscoe M, Widlitz MD (1998): Cetirizine, loratadine, or placebo in subjects with seasonal allergic rhinitis: effects after controlled ragweed pollen challenge in an environmental exposure unit. Allergy Clin Immunol 101: 638–645.
Durham SR, Walker SM, Varga EM, Jacobson MR, O’Brian F, Noble W et al. (1999): Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 341: 468–475.
Fricke U, Schwabe U (2004): Neue Arzneimittel. In Schwabe U, Paffrath D (Hrsg): Arzneiverordnungs-Report 2003. Springer-Verlag, Berlin u. a., S. 24–87.
Frossard N, Lacronique J, Melac M, Benabdesselam O, Bran JJ et al. (1997): Onset of action in the nasal antihistaminic effect of cetirizine and loratadine in patients with allergic rhinitis. Allergy 52: 205–209.
Guez S, Vatrinet C, Fadel R, Andre C (2000): House-dust-mite sublingual-swallow immunotherapy (SLIT) in perennial rhinitis: a double-blind, placebo-controlled study. Allergy 55: 369–375.
Hoff M, Krail M, Kästner M, Haustein D, Vieths S (2002): Fusarium culmorum causes strong degradation of pollen allergens in extract mixtures. J Allergy Clin Immunol 109:96–101.
Hunt KJ, Valentine MD, Sobotka AK, Benton AW, Amodio FJ, Lichtenstein LM (1978): A controlled trial of immunotherapy in insect hypersensitivity. N Engl J Med 299:157–161.
Lüderitz-Püchel U, May S, Haustein D (1996): Zwischenfälle nach Hyposensibilisierung. Münch Med Wschr 138:129–132.
Mellerup MT, Hahn GW, Poulsen LK, Mailing HJ (2000): Safety of allergen-specific immunotherapy. Relation between dosage regimen, allergen extract, disease and systemic side-effects during induciton treatment. Clin Exp Allergy. 30:1423–1429.
Meltzer EO, Weiler JM, Widlitz MD (1996): Comparative outdoor study of the efficacy, onset and duration of action, and safety of cetirizine, loratadine, and placebo for seasonal allergic rhinitis. J Allergy Clin Immunol 97: 617–626.
Möller C, Dreborg S, Ferdousi HA, Halken S, H0st A, Jacobsen L et al. (2002): Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-Study). J Allergy Clin Immunol 109: 251–256.
Olsen OT, Larsen KR, Jacobsan L, Svedsen UG (1997): A 1-year placebo-controlled, double-blind house-dust-mite immunotherapy study in asthmatic adults. Allergy 52: 853–859.
O’Neill SM, Forsyth A (1988): Urticaria. Prescribers J 28:14–20.
Petersen BN, Janniche H, Munch EP, Wihl JA, Bowadt H, Ipsen H, Lowenstein H (1988): Immunotherapy with partially purified and standardized tree pollen extracts. I. Clinical results from a three-year double-blind study of patients treated with pollen extracts either of birch or combinations of alder, birch and hazel. Allergy 43: 353–362.
Pichler CE, Helbling A, Pichler WJ (2001): Three years of specific immunotherapy with house-dust-mite extracts in patients with rhinitis and asthma: significant improvement of allergen-specific parameters and of nonspecific bronchial hyperreactivity. Allergy 56: 301–306.
Pichler CE, Marquardsen A, Sparholt S, Lowenstein H, Bircher A, Bischof M, Pichler WJ (1997): Specific immunotherapy with Dermatophagoides ptheronyssinus and D. farinae results in decreased bronchial hyperreactivity. Allergy 52: 274–283.
Reid MJ, Lockey RF, Turkeltaub PC, Platts-Mills TA (1993): Survey of fatalities from skin testing and immunotherapy 1985–1989. J Allergy Clin Immunol 92: 6–15.
Routledge PA, Lindquist M, Edwards IR (1999): Spontaneous reporting of suspected adverse reactions to antihistamines: a national and international perspective. Clin Exp Allergy 29(Suppl 3): 240–246.
Ruëff F, Wenderoth A, Przybilla B (2001): Patients still reacting to a sting challenge while receiving conventional Hymenoptera venom immunotherapy are protected by increased venom doses. J Allergy Clin Immunol 108:1027–1032.
Spencer CM, Faulds D, Peters DH (1993): Cetirizine: a reappraisal of its pharmacological properties and therapeutic use in selected allergic disorders. Drugs 46: 1055–80.
Warner JO, Price JF, Soothill JF, Hey EN (1978): Controlled trial of hyposensitisation to Dermatophagoides pteronyssinus in children with asthma. Lancet 2: 912–915.
WHO Position Paper (1998): Allergen immunotherapy: therapeutic vaccines for allergic diseases. Allergy 53(Suppl 1): 1–42.
Wilson DR, Torres LI, Durham SR. (2003): Sublingual immunotherapy for allergic rhinitis (Cochrane Review). In: The Cochrane Library, Issue 2, 2003. Oxford: Update Software.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2004 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Zawinell, A., Schwabe, U. (2004). Antiallergika. In: Schwabe, U., Paffrath, D. (eds) Arzneiverordnungs-Report 2004. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-18513-7_7
Download citation
DOI: https://doi.org/10.1007/978-3-642-18513-7_7
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-21359-8
Online ISBN: 978-3-642-18513-7
eBook Packages: Springer Book Archive